New and future strategies to improve asthma control in children

Journal of Allergy and Clinical Immunology

Volumn 136, Issue 4, 2015, Pages 848-859

  Anderson, William C ^a,b   Szefler, Stanley J ^a,b  

^a CHILDREN S HOSPITAL COLORADO   (United States)

^b Children's Hospital Colorado   (United States)

Author keywords

Asthma; asthma control; asthma exacerbations; biomarkers; dupilumab; inhaled corticosteroids; lebrikizumab; long acting adrenergic agonists; mepolizumab; omalizumab; reslizumab; severe asthma; therapeutics

Indexed keywords

BECLOMETASONE; BUDESONIDE; DUPILUMAB; FLUTICASONE PROPIONATE; FORMOTEROL; LEBRIKIZUMAB; MEPOLIZUMAB; OMALIZUMAB; RESLIZUMAB; TIOTROPIUM BROMIDE; ANTIASTHMATIC AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID;

ASTHMA; DISEASE CONTROL; DISEASE SEVERITY; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; MEDICATION COMPLIANCE; PHENOTYPE; PRIORITY JOURNAL; REVIEW; ADOLESCENT; ADULT; ANIMAL; BIOLOGICAL THERAPY; CHILD; INHALATIONAL DRUG ADMINISTRATION;

ADMINISTRATION, INHALATION; ADOLESCENT; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; ADULT; ANIMALS; ANTI-ASTHMATIC AGENTS; ASTHMA; BIOLOGICAL THERAPY; CHILD; HUMANS; MEDICATION ADHERENCE;

EID: 84943451226     PISSN: 00916749     EISSN: 10976825     Source Type: Journal    
DOI: 10.1016/j.jaci.2015.07.007     Document Type: Article

References (130)

1. S.J. Szefler, J.F. Chmiel, A.M. Fitzpatrick, G. Giacoia, T.P. Green, D.J. Jackson, and et al. Asthma across the ages: knowledge gaps in childhood asthma J Allergy Clin Immunol 133 2014 3 14
2. D.K. Radhakrishnan, S.D. Dell, A. Guttmann, S.Z. Shariff, K. Liu, and T. To Trends in the age of diagnosis of childhood asthma J Allergy Clin Immunol 134 2014 1057 1062.e5
3. W.J. Morgan, D.A. Stern, D.L. Sherrill, S. Guerra, C.J. Holberg, T.W. Guilbert, and et al. Outcome of asthma and wheezing in the first 6 years of life: follow-up through adolescence Am J Respir Crit Care Med 172 2005 1253 1258
4. R.C. Strunk, S.T. Weiss, K.P. Yates, J. Tonascia, R.S. Zeiger, S.J. Szefler, and et al. Mild to moderate asthma affects lung growth in children and adolescents J Allergy Clin Immunol 118 2006 1040 1047
5. C.J. Lodge, A.J. Lowe, K.J. Allen, S. Zaloumis, L.C. Gurrin, M.C. Matheson, and et al. Childhood wheeze phenotypes show less than expected growth in FEV1 across adolescence Am J Respir Crit Care Med 189 2014 1351 1358
6. A. Tai, H. Tran, M. Roberts, N. Clarke, A.M. Gibson, S. Vidmar, and et al. Outcomes of childhood asthma to the age of 50 years J Allergy Clin Immunol 133 2014 1572 1578.e3
7. T.W. Guilbert, W.J. Morgan, R.S. Zeiger, D.T. Mauger, S.J. Boehmer, S.J. Szefler, and et al. Long-term inhaled corticosteroids in preschool children at high risk for asthma N Engl J Med 354 2006 1985 1997
8. C.S. Murray, A. Woodcock, S.J. Langley, J. Morris, A. Custovic IFWIN study team Secondary prevention of asthma by the use of Inhaled Fluticasone propionate in Wheezy INfants (IFWIN): double-blind, randomised, controlled study Lancet 368 2006 754 762
9. S.J. Szefler Advances in pediatric asthma in 2011: moving forward J Allergy Clin Immunol 129 2012 60 68
10. EPR. Guidelines for the diagnosis and management of asthma - summary report 2007 J Allergy Clin Immunol 120 suppl 2007 S94 S138
11. T. Haselkorn, J.E. Fish, R.S. Zeiger, S.J. Szefler, D.P. Miller, B.E. Chipps, and et al. Consistently very poorly controlled asthma, as defined by the impairment domain of the Expert Panel Report 3 guidelines, increases risk for future severe asthma exacerbations in The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study J Allergy Clin Immunol 124 2009 895 902 e1-4
12. M.N. Eakin, and C.S. Rand Improving patient adherence with asthma self-management practices: what works? Ann Allergy Asthma Immunol 109 2012 90 92
13. J.A. Krishnan, B.G. Bender, F.S. Wamboldt, S.J. Szefler, N.F. Adkinson Jr., R.S. Zeiger, and et al. Adherence to inhaled corticosteroids: an ancillary study of the Childhood Asthma Management Program clinical trial J Allergy Clin Immunol 129 2012 112 118
14. M. Engelkes, H.M. Janssens, J.C. de Jongste, M.C. Sturkenboom, and K.M. Verhamme Medication adherence and the risk of severe asthma exacerbations: a systematic review Eur Respir J 45 2015 396 407
15. A.G. Weinstein Asthma adherence management for the clinician J Allergy Clin Immunol Pract 1 2013 123 128
16. B. Bender, F.S. Wamboldt, S.L. O'Connor, C. Rand, S. Szefler, H. Milgrom, and et al. Measurement of children's asthma medication adherence by self report, mother report, canister weight, and Doser CT Ann Allergy Asthma Immunol 85 2000 416 421
17. M. Patel, K. Perrin, A. Pritchard, M. Williams, M. Wijesinghe, M. Weatherall, and et al. Accuracy of patient self-report as a measure of inhaled asthma medication use Respirology 18 2013 546 552
18. M. Arga, H. Sahbaz, A. Bakirtas, I. Turktas, and M.S. Demirsoy Does self-monitoring by means of symptom diaries improve asthma control in children? J Asthma 51 2014 299 305
19. J.A. Krishnan, R.F. Lemanske Jr., G.J. Canino, K.S. Elward, M. Kattan, E.C. Matsui, and et al. Asthma outcomes: symptoms J Allergy Clin Immunol 129 suppl 2012 S124 S135
20. T.W. Guilbert, L.B. Bacharier, and A.M. Fitzpatrick Severe asthma in children J Allergy Clin Immunol Pract 2 2014 489 500
21. K.F. Chung, S.E. Wenzel, J.L. Brozek, A. Bush, M. Castro, P.J. Sterk, and et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma Eur Respir J 43 2014 343 373
22. P.D. Robinson, and P. Van Asperen Newer treatments in the management of pediatric asthma Paediatr Drugs 15 2013 291 302
23. J.X. Lee, H.A. Wojtczak, A.M. Wachter, M.L. Lee, L. Burns, D. Chen, and et al. Understanding asthma medical nonadherence in an adult and pediatric population J Allergy Clin Immunol Pract 3 2015 436 437
24. A.H. Chan, H.K. Reddel, A. Apter, M. Eakin, K. Riekert, and J.M. Foster Adherence monitoring and e-health: how clinicians and researchers can use technology to promote inhaler adherence for asthma J Allergy Clin Immunol Pract 1 2013 446 454
25. A.H. Chan, A.W. Stewart, J. Harrison, C.A. Camargo Jr., P.N. Black, and E.A. Mitchell The effect of an electronic monitoring device with audiovisual reminder function on adherence to inhaled corticosteroids and school attendance in children with asthma: a randomised controlled trial Lancet Respir Med 3 2015 210 219
26. A.H. Chan, J. Harrison, P.N. Black, E.A. Mitchell, and J.M. Foster Using electronic monitoring devices to measure inhaler adherence: a practical guide for clinicians J Allergy Clin Immunol Pract 3 2015 335 349.e5
27. S.J. Szefler Monitoring and adherence in asthma management Lancet Respir Med 3 2015 175 176
28. B.G. Bender Advancing the science of adherence measurement: implications for the clinician J Allergy Clin Immunol Pract 1 2013 92 93
29. M. Patel, J. Pilcher, J. Travers, K. Perrin, D. Shaw, P. Black, and et al. Use of metered-dose inhaler electronic monitoring in a real-world asthma randomized controlled trial J Allergy Clin Immunol Pract 1 2013 83 91
30. T. Charles, D. Quinn, M. Weatherall, S. Aldington, R. Beasley, and S. Holt An audiovisual reminder function improves adherence with inhaled corticosteroid therapy in asthma J Allergy Clin Immunol 119 2007 811 816
31. P. Black, E. Garratt, L. Noonan, C. Arandjus, B. Salmon, and G. Sutherland An inhaler with ringtones improves compliance with inhaled steroids in childhood asthma Am J Respir Crit Care Med 117 2008 A615
32. S.W. Burgess, P.D. Sly, and S.G. Devadason Providing feedback on adherence increases use of preventive medication by asthmatic children J Asthma 47 2010 198 201
33. J.M. Foster, T. Usherwood, L. Smith, S.M. Sawyer, W. Xuan, C.S. Rand, and et al. Inhaler reminders improve adherence with controller treatment in primary care patients with asthma J Allergy Clin Immunol 134 2014 1260 1268.e3
34. A. Zajicek, and J.S. Barrett The grand challenges in obstetric and pediatric pharmacology Front Pharmacol 4 2013 170
35. D. Silva, I. Ansotegui, and M. Morais-Almeida Off-label prescribing for allergic diseases in children World Allergy Organ J 7 2014 4
36. F.T. Bourgeois, S. Murthy, C. Pinto, K.L. Olson, J.P. Ioannidis, and K.D. Mandl Pediatric versus adult drug trials for conditions with high pediatric disease burden Pediatrics 130 2012 285 292
37. M.D. Cabana, S.J. Kunselman, S.M. Nyenhuis, and M.E. Wechsler Researching asthma across the ages: insights from the National Heart, Lung, and Blood Institute's Asthma Network J Allergy Clin Immunol 133 2014 27 33
38. A.R. Smyth, A. Barbato, N. Beydon, H. Bisgaard, K. de Boeck, P. Brand, and et al. Respiratory medicines for children: current evidence, unlicensed use and research priorities Eur Respir J 35 2010 247 265
39. G. Winzenburg More than 5 years of European Paediatric regulation: statistics and industrial experience Int J Pharm 469 2014 260 262
40. M.B. Reddy, J. Doshi, R. Covar, and J.D. Spahn The changing face of severe childhood asthma: a comparison of two cohorts of children evaluated at National Jewish Health over the past 20 years Allergy Asthma Proc 35 2014 119 125
41. T.W. Guilbert, D.T. Mauger, D.B. Allen, R.S. Zeiger, R.F. Lemanske Jr., S.J. Szefler, and et al. Growth of preschool children at high risk for asthma 2 years after discontinuation of fluticasone J Allergy Clin Immunol 128 2011 956 963 e1-7
42. H.W. Kelly, A.L. Sternberg, R. Lescher, A.L. Fuhlbrigge, P. Williams, R.S. Zeiger, and et al. Effect of inhaled glucocorticoids in childhood on adult height N Engl J Med 367 2012 904 912
43. R.J. Martin, S.J. Szefler, V.M. Chinchilli, M. Kraft, M. Dolovich, H.A. Boushey, and et al. Systemic effect comparisons of six inhaled corticosteroid preparations Am J Respir Crit Care Med 165 2002 1377 1383
44. H. Bisgaard, and S. Szefler Long-acting beta2 agonists and paediatric asthma Lancet 367 2006 286 288
45. C.A. Sorkness, R.F. Lemanske Jr., D.T. Mauger, S.J. Boehmer, V.M. Chinchilli, F.D. Martinez, and et al. Long-term comparison of 3 controller regimens for mild-moderate persistent childhood asthma: the Pediatric Asthma Controller Trial J Allergy Clin Immunol 119 2007 64 72
46. K.E. Wells, E.L. Peterson, B.K. Ahmedani, R.K. Severson, J. Gleason-Comstock, and L.K. Williams The relationship between combination inhaled corticosteroid and long-acting beta-agonist use and severe asthma exacerbations in a diverse population J Allergy Clin Immunol 129 2012 1274 1279.e2
47. R.F. Lemanske Jr., D.T. Mauger, C.A. Sorkness, D.J. Jackson, S.J. Boehmer, F.D. Martinez, and et al. Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids N Engl J Med 362 2010 975 985
48. Communication FDS. FDA requires post-market safety trials for long-acting beta-agonists (LABAs) 2011. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm251512.htm. Accessed May 20, 2015.
49. R.S. Zeiger, D. Mauger, L.B. Bacharier, T.W. Guilbert, F.D. Martinez, R.F. Lemanske Jr., and et al. Daily or intermittent budesonide in preschool children with recurrent wheezing N Engl J Med 365 2011 1990 2001
50. F.D. Martinez, V.M. Chinchilli, W.J. Morgan, S.J. Boehmer, R.F. Lemanske Jr., D.T. Mauger, and et al. Use of beclomethasone dipropionate as rescue treatment for children with mild persistent asthma (TREXA): a randomised, double-blind, placebo-controlled trial Lancet 377 2011 650 657
51. R. Beasley, M. Weatherall, P. Shirtcliffe, R. Hancox, and H.K. Reddel Combination corticosteroid/beta-agonist inhaler as reliever therapy: a solution for intermittent and mild asthma? J Allergy Clin Immunol 133 2014 39 41
52. P.M. O'Byrne, H. Bisgaard, P.P. Godard, M. Pistolesi, M. Palmqvist, Y. Zhu, and et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma Am J Respir Crit Care Med 171 2005 129 136
53. H. Bisgaard, P. Le Roux, D. Bjamer, A. Dymek, J.H. Vermeulen, and C. Hultquist Budesonide/formoterol maintenance plus reliever therapy: a new strategy in pediatric asthma Chest 130 2006 1733 1743
54. GlaxoSmithKline. Advair: FDA Prescribing Information. Updated April 2008. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2008/021077s029lbl.pdf. Accessed May 20, 2015.
55. AstraZeneca. Symbicort: FDA Prescribing Information 2006. Available at: http://www1.astrazeneca-us.com/pi/symbicort.pdf. Accessed May 20, 2015.
56. Merck. Dulera: FDA Prescribing Information. Updated January 2015. Available at: https://www.merck.com/product/usa/pi-circulars/d/dulera/dulera-pi.pdf. Accessed May 20, 2015.
57. M. Sadatsafavi, L. Lynd, C. Marra, P. Bedouch, and M. Fitzgerald Comparative outcomes of leukotriene receptor antagonists and long-acting beta-agonists as add-on therapy in asthmatic patients: a population-based study J Allergy Clin Immunol 132 2013 63 69
58. L.J. Bauman, E. Wright, F.E. Leickly, E. Crain, D. Kruszon-Moran, S.L. Wade, and et al. Relationship of adherence to pediatric asthma morbidity among inner-city children Pediatrics 110 2002 e6
59. J.F. Guest, A.M. Davie, F.J. Ruiz, and M.J. Greener Switching asthma patients to a once-daily inhaled steroid improves compliance and reduces healthcare costs Prim Care Respir J 14 2005 88 98
60. R.A. Nathan, A. D'Urzo, V. Blazhko, and K. Kaiser Safety and efficacy of fluticasone/formoterol combination therapy in adolescent and adult patients with mild-to-moderate asthma: a randomised controlled trial BMC Pulm Med 12 2012 67
61. A. Bodzenta-Lukaszyk, R. Buhl, B. Balint, M. Lomax, K. Spooner, and S. Dissanayake Fluticasone/formoterol combination therapy versus budesonide/formoterol for the treatment of asthma: a randomized, controlled, non-inferiority trial of efficacy and safety J Asthma 49 2012 1060 1070
62. J. Corren, L.E. Mansfield, T. Pertseva, V. Blahzko, and K. Kaiser Efficacy and safety of fluticasone/formoterol combination therapy in patients with moderate-to-severe asthma Respir Med 107 2013 180 195
63. A. Woodcock, E.R. Bleecker, J. Lotvall, P.M. O'Byrne, E.D. Bateman, H. Medley, and et al. Efficacy and safety of fluticasone furoate/vilanterol compared with fluticasone propionate/salmeterol combination in adult and adolescent patients with persistent asthma: a randomized trial Chest 144 2013 1222 1229
64. A. Oliver, S. VanBuren, A. Allen, M. Hamilton, L. Tombs, A. Inamdar, and et al. Tolerability of fluticasone furoate/vilanterol combination therapy in children aged 5 to 11 years with persistent asthma Clin Ther 36 2014 928 939.e1
65. GlaxoSmithKline. Breo Ellipta: FDA Prescribing Information. Updated April 2015. Available at: https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing-Information/Breo-Ellipta/pdf/BREO-ELLIPTA-PI-MG.PDF. Accessed May 20, 2015.
66. S.P. Peters, S.J. Kunselman, N. Icitovic, W.C. Moore, R. Pascual, B.T. Ameredes, and et al. Tiotropium bromide step-up therapy for adults with uncontrolled asthma N Engl J Med 363 2010 1715 1726
67. D.P. Tashkin, B. Celli, S. Senn, D. Burkhart, S. Kesten, S. Menjoge, and et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease N Engl J Med 359 2008 1543 1554
68. H.A. Kerstjens, T.B. Casale, E.R. Bleecker, E.O. Meltzer, E. Pizzichini, O. Schmidt, and et al. Tiotropium or salmeterol as add-on therapy to inhaled corticosteroids for patients with moderate symptomatic asthma: two replicate, double-blind, placebo-controlled, parallel-group, active-comparator, randomised trials Lancet Respir Med 3 2015 367 376
69. H.A. Kerstjens, M. Engel, R. Dahl, P. Paggiaro, E. Beck, M. Vandewalker, and et al. Tiotropium in asthma poorly controlled with standard combination therapy N Engl J Med 367 2012 1198 1207
70. H.A. Kerstjens, B. Disse, W. Schroder-Babo, T.A. Bantje, M. Gahlemann, R. Sigmund, and et al. Tiotropium improves lung function in patients with severe uncontrolled asthma: a randomized controlled trial J Allergy Clin Immunol 128 2011 308 314
71. C. Vogelberg, P. Moroni-Zentgraf, M. Leonaviciute-Klimantaviciene, R. Sigmund, E. Hamelmann, M. Engel, and et al. A randomised dose-ranging study of tiotropium Respimat(R) in children with symptomatic asthma despite inhaled corticosteroids Respir Res 16 2015 20
72. C. Vogelberg, M. Engel, P. Moroni-Zentgraf, M. Leonaviciute-Klimantaviciene, R. Sigmund, J. Downie, and et al. Tiotropium in asthmatic adolescents symptomatic despite inhaled corticosteroids: a randomised dose-ranging study Respir Med 108 2014 1268 1276
73. E. Hamelmann, A. Boner, J. Bernstein, P. Moroni-Zentgraf, M. Engel, M. Avis, A. Unseld, and et al. 1-year efficacy and safety study of tiotropium Respimat add-on to ICS in adolescent patients with symptomatic asthma Eur Respir J 44 suppl 58 2014 1889
74. N. Rabinovitch, D.T. Mauger, N. Reisdorph, R. Covar, J. Malka, R.F. Lemanske Jr., and et al. Predictors of asthma control and lung function responsiveness to step 3 therapy in children with uncontrolled asthma J Allergy Clin Immunol 133 2014 350 356
75. J. Malka, D.T. Mauger, R. Covar, N. Rabinovitch, R.F. Lemanske Jr., J.D. Spahn, and et al. Eczema and race as combined determinants for differential response to step-up asthma therapy J Allergy Clin Immunol 134 2014 483 485
76. E.R. Sutherland, W.W. Busse National Heart, Lung, and Blood Institute's AsthmaNet Designing clinical trials to address the needs of childhood and adult asthma: the National Heart, Lung, and Blood Institute's AsthmaNet J Allergy Clin Immunol 133 2014 34 38.e1
77. S.P. Peters, E.R. Bleecker, S.J. Kunselman, N. Icitovic, W.C. Moore, R. Pascual, and et al. Predictors of response to tiotropium versus salmeterol in asthmatic adults J Allergy Clin Immunol 132 2013 1068 1074.e1
78. O. Boyman, C. Kaegi, M. Akdis, S. Bavbek, A. Bossios, A. Chatzipetrou, and et al. EAACI IG Biologicals task force paper on the use of biologic agents in allergic disorders Allergy 70 2015 727 754
79. S.T. Holgate Pathophysiology of asthma: what has our current understanding taught us about new therapeutic approaches? J Allergy Clin Immunol 128 2011 495 505
80. S.J. Szefler Advances in pediatric asthma in 2014: Moving toward a population health perspective J Allergy Clin Immunol 135 2015 644 652
81. W.C. Moore, D.A. Meyers, S.E. Wenzel, W.G. Teague, H. Li, X. Li, and et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program Am J Respir Crit Care Med 181 2010 315 323
82. A.M. Fitzpatrick, W.G. Teague, D.A. Meyers, S.P. Peters, X. Li, H. Li, and et al. Heterogeneity of severe asthma in childhood: confirmation by cluster analysis of children in the National Institutes of Health/National Heart, Lung, and Blood Institute Severe Asthma Research Program J Allergy Clin Immunol 127 2011 382 389 e1-13
83. T.S. Chang, R.F. Lemanske Jr., D.T. Mauger, A.M. Fitzpatrick, C.A. Sorkness, S.J. Szefler, and et al. Childhood asthma clusters and response to therapy in clinical trials J Allergy Clin Immunol 133 2014 363 369
84. J.A. Howrylak, A.L. Fuhlbrigge, R.C. Strunk, R.S. Zeiger, S.T. Weiss, B.A. Raby, and et al. Classification of childhood asthma phenotypes and long-term clinical responses to inhaled anti-inflammatory medications J Allergy Clin Immunol 133 2014 1289 1300 e1-12
85. M. Schatz, and L. Rosenwasser The allergic asthma phenotype J Allergy Clin Immunol Pract 2 2014 645 649
86. S. Romanet-Manent, D. Charpin, A. Magnan, A. Lanteaume, D. Vervloet EGEA Cooperative Group Allergic vs nonallergic asthma: what makes the difference? Allergy 57 2002 607 613
87. A.M. Fitzpatrick, and W.G. Teague Severe asthma in children: insights from the National Heart, Lung, and Blood Institute's Severe Asthma Research Program Pediatr Allergy Immunol Pulmonol 23 2010 131 138
88. J. Paton Severe asthma in children. Symposium: respiratory medicine J Paediatr Child Health 17 2007 180 187
89. P.G. Gibson, J.L. Simpson, R. Hankin, H. Powell, and R.L. Henry Relationship between induced sputum eosinophils and the clinical pattern of childhood asthma Thorax 58 2003 116 121
90. X.Y. He, J.L. Simpson, and F. Wang Inflammatory phenotypes in stable and acute childhood asthma Paediatr Respir Rev 12 2011 165 169
91. A.M. Fitzpatrick, B.M. Gaston, S.C. Erzurum, and W.G. Teague National Institutes of Health/National Heart, Lung, and Blood Institute Severe Asthma Research Program. Features of severe asthma in school-age children: atopy and increased exhaled nitric oxide J Allergy Clin Immunol 118 2006 1218 1225
92. J. Darveaux, and W.W. Busse Biologics in asthma - the next step toward personalized treatment J Allergy Clin Immunol Pract 3 2015 152 161
93. E. Zoratti, S. Havstad, G. Wegienka, C. Nicholas, K.R. Bobbitt, K.J. Woodcroft, and et al. Differentiating asthma phenotypes in young adults through polyclonal cytokine profiles Ann Allergy Asthma Immunol 113 2014 25 30
94. C.J. Bossley, L. Fleming, A. Gupta, N. Regamey, J. Frith, T. Oates, and et al. Pediatric severe asthma is characterized by eosinophilia and remodeling without T(H)2 cytokines J Allergy Clin Immunol 129 2012 974 982.e13
95. S.J. Szefler Advances in pediatric asthma in 2012: moving toward asthma prevention J Allergy Clin Immunol 131 2013 36 46
96. M. Humbert, W. Busse, N.A. Hanania, P.J. Lowe, J. Canvin, V.J. Erpenbeck, and et al. Omalizumab in asthma: an update on recent developments J Allergy Clin Immunol Pract 2 2014 525 536.e1
97. M. Bonini, G. Di Maria, P. Paggiaro, A. Rossi, G. Senna, M. Triggiani, and et al. Potential benefit of omalizumab in respiratory diseases Ann Allergy Asthma Immunol 113 2014 513 519
98. K. Kuhl, and N.A. Hanania Targeting IgE in asthma Curr Opin Pulm Med 18 2012 1 5
99. J. Bousquet, P. Cabrera, N. Berkman, R. Buhl, S. Holgate, S. Wenzel, and et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma Allergy 60 2005 302 308
100. S.T. Holgate, A.G. Chuchalin, J. Hebert, J. Lotvall, G.B. Persson, K.F. Chung, and et al. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma Clin Exp Allergy 34 2004 632 638
101. Genentech I. Xolair: FDA prescribing information. Updated September 2014. Available at: http://www.gene.com/download/pdf/xolair-prescribing.pdf. Accessed May 6, 2015.
102. N.A. Hanania, O. Alpan, D.L. Hamilos, J.J. Condemi, I. Reyes-Rivera, J. Zhu, and et al. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial Ann Intern Med 154 2011 573 582
103. M. Humbert, R. Beasley, J. Ayres, R. Slavin, J. Hebert, J. Bousquet, and et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE Allergy 60 2005 309 316
104. W.W. Busse, W.J. Morgan, P.J. Gergen, H.E. Mitchell, J.E. Gern, A.H. Liu, and et al. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children N Engl J Med 364 2011 1005 1015
105. H. Milgrom, W. Berger, A. Nayak, N. Gupta, S. Pollard, M. McAlary, and et al. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab) Pediatrics 108 2001 E36
106. B. Lanier, T. Bridges, M. Kulus, A.F. Taylor, I. Berhane, and C.F. Vidaurre Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma J Allergy Clin Immunol 124 2009 1210 1216
107. M. Brodlie, M.C. McKean, S. Moss, and D.A. Spencer The oral corticosteroid-sparing effect of omalizumab in children with severe asthma Arch Dis Child 97 2012 604 609
108. L. Hendeles, Y.R. Khan, J.J. Shuster, S.E. Chesrown, and M. Abu-Hasan Omalizumab therapy for asthma patients with poor adherence to inhaled corticosteroid therapy Ann Allergy Asthma Immunol 114 2015 58 62.e2
109. N.A. Hanania, S. Wenzel, K. Rosen, H.J. Hsieh, S. Mosesova, D.F. Choy, and et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study Am J Respir Crit Care Med 187 2013 804 811
110. M.L. Fajt, and S.E. Wenzel Asthma phenotypes and the use of biologic medications in asthma and allergic disease: the next steps toward personalized care J Allergy Clin Immunol 135 2015 299 311
111. C.A. Sorkness, J.J. Wildfire, A. Calatroni, H.E. Mitchell, W.W. Busse, G.T. O'Connor, and et al. Reassessment of omalizumab-dosing strategies and pharmacodynamics in inner-city children and adolescents J Allergy Clin Immunol Pract 1 2013 163 171
112. W. Busse, S. Spector, K. Rosen, Y. Wang, and O. Alpan High eosinophil count: a potential biomarker for assessing successful omalizumab treatment effects J Allergy Clin Immunol 132 2013 485 486.e11
113. P. Haldar, C.E. Brightling, B. Hargadon, S. Gupta, W. Monteiro, A. Sousa, and et al. Mepolizumab and exacerbations of refractory eosinophilic asthma N Engl J Med 360 2009 973 984
114. P. Nair, M.M. Pizzichini, M. Kjarsgaard, M.D. Inman, A. Efthimiadis, E. Pizzichini, and et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia N Engl J Med 360 2009 985 993
115. P. Flood-Page, C. Swenson, I. Faiferman, J. Matthews, M. Williams, L. Brannick, and et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma Am J Respir Crit Care Med 176 2007 1062 1071
116. I.D. Pavord, S. Korn, P. Howarth, E.R. Bleecker, R. Buhl, O.N. Keene, and et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial Lancet 380 2012 651 659
117. H.G. Ortega, M.C. Liu, I.D. Pavord, G.G. Brusselle, J.M. FitzGerald, A. Chetta, and et al. Mepolizumab treatment in patients with severe eosinophilic asthma N Engl J Med 371 2014 1198 1207
118. E.H. Bel, S.E. Wenzel, P.J. Thompson, C.M. Prazma, O.N. Keene, S.W. Yancey, and et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma N Engl J Med 371 2014 1189 1197
119. R.A. Dweik, R.L. Sorkness, S. Wenzel, J. Hammel, D. Curran-Everett, S.A. Comhair, and et al. Use of exhaled nitric oxide measurement to identify a reactive, at-risk phenotype among patients with asthma Am J Respir Crit Care Med 181 2010 1033 1041
120. M. Castro, S. Mathur, F. Hargreave, L.P. Boulet, F. Xie, J. Young, and et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study Am J Respir Crit Care Med 184 2011 1125 1132
121. M. Castro, J. Zangrilli, M.E. Wechsler, E.D. Bateman, G.G. Brusselle, P. Bardin, and et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials Lancet Respir Med 3 2015 355 366
122. J. Corren, R.F. Lemanske, N.A. Hanania, P.E. Korenblat, M.V. Parsey, J.R. Arron, and et al. Lebrikizumab treatment in adults with asthma N Engl J Med 365 2011 1088 1098
123. P.G. Woodruff, B. Modrek, D.F. Choy, G. Jia, A.R. Abbas, A. Ellwanger, and et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma Am J Respir Crit Care Med 180 2009 388 395
124. G. Jia, R.W. Erickson, D.F. Choy, S. Mosesova, L.C. Wu, O.D. Solberg, and et al. Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients J Allergy Clin Immunol 130 2012 647 654.e10
125. B. Zeskind Lebrikizumab treatment in adults with asthma N Engl J Med 365 2011 2432 author reply 2433-4
126. K. Chibana, J.B. Trudeau, A.T. Mustovich, H. Hu, J. Zhao, S. Balzar, and et al. IL-13 induced increases in nitrite levels are primarily driven by increases in inducible nitric oxide synthase as compared with effects on arginases in human primary bronchial epithelial cells Clin Exp Allergy 38 2008 936 946
127. M. Noonan, P. Korenblat, S. Mosesova, H. Scheerens, J.R. Arron, Y. Zheng, and et al. Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids J Allergy Clin Immunol 132 2013 567 574.e12
128. H.M. Anderson, R.F. Lemanske Jr., J.R. Arron, C. Holweg, V. Rajamanickam, J.E. Gern, and D.J. Jackson Developmental assessment of serum periostin as an asthma biomarker in children J Allergy Clin Immunol 133 suppl 2014 AB85
129. J.S. Song, J.S. You, S.I. Jeong, S. Yang, I.T. Hwang, Y.G. Im, and et al. Serum periostin levels correlate with airway hyper-responsiveness to methacholine and mannitol in children with asthma Allergy 70 2015 674 681
130. S. Wenzel, L. Ford, D. Pearlman, S. Spector, L. Sher, F. Skobieranda, and et al. Dupilumab in persistent asthma with elevated eosinophil levels N Engl J Med 368 2013 2455 2466